Related Experiment Video

Updated: Sep 29, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia

Eriko Morishita1, Shinji Minami, Chizuko Ishino

  • 1Department of Laboratory Sciences, School of Health Science, Kanazawa University, Japan. eriko@med3.m.kanazawa-u.ac.jp

Journal of Atherosclerosis and Thrombosis
|September 20, 2002
PubMed

Insights

Atorvastatin significantly reduced factor VII activity and antigen levels in hyperlipidemic patients. This may lower thrombotic potential and reduce coronary heart disease risk.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Hyperlipidemia is a significant risk factor for cardiovascular disease.
  • Factor VII plays a role in the coagulation cascade and thrombotic events.
  • Statins, like atorvastatin, are widely used to manage hyperlipidemia.

Purpose of the Study:

  • To investigate the effect of atorvastatin on plasma levels of factor VII in hyperlipidemic patients.
  • To explore the correlation between changes in lipid profiles and factor VII levels.
  • To assess the potential impact of atorvastatin on thrombotic risk.

Main Methods:

  • A study involving 30 hyperlipidemic patients.
  • 12 weeks of treatment with atorvastatin.
  • Measurement of factor VII activity (FVIIc), factor VII antigen (FVIIag), activated factor VII (FVIIa), fibrinogen, and plasminogen activator inhibitor-1 levels.
  • Correlation analysis between lipid concentrations and factor VII levels.

Main Results:

  • Atorvastatin treatment led to significant decreases in FVIIc (13%) and FVIIag (12%) levels (p < 0.0001).
  • Decreased serum triglyceride concentrations correlated with reduced FVIIc and FVIIag levels.
  • No significant changes were observed in FVIIa, fibrinogen, or plasminogen activator inhibitor-1 levels.

Conclusions:

  • Atorvastatin effectively reduces factor VII levels in hyperlipidemic patients.
  • The reduction in factor VII may contribute to a decreased thrombotic potential.
  • This effect of atorvastatin could potentially lead to fewer thromboembolic events and reduced coronary heart disease.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...